Azenta, Inc.
AZTA Small CapHealthcare · Medical Instruments & Supplies
Mis à jour: Jun 18, 2026, 22:21 UTC
Price Chart
Indicateurs clés
Valuation Analysis
About the Company
Azenta, Inc. en bref
Azenta, Inc. (AZTA) is currently trading at 20,34 € with a market capitalization of 938 M €. The 52-week range spans from 13,90 € to 36,42 €; the current price is 44.1% below the yearly high. Year-over-year revenue growth stands at +1.0%.
💰 Dividende
Azenta, Inc. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.
📊 Avis des analystes
5 analystes évaluent Azenta, Inc. (AZTA) au consensus : Acheter. L'objectif de cours moyen est de 22,86 €, soit un potentiel de +12.4% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 17,45 € à 28,80 €.
Azenta, Inc. : la thèse d'investissement en détail
Azenta, Inc. (AZTA) operates in the Healthcare — specifically Medical Instruments & Supplies — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.
Le scénario baissier
Revenue growth has slowed to just 1%, which is below nominal GDP — the business is no longer outgrowing the broader economy. Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders. Short interest sits at 20.04% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.
Valorisation en contexte
With a PEG ratio of 0.53, the price-to-earnings multiple is actually below the company's growth rate — classic value-meets-growth territory that Peter Lynch would have called a 'GARP' opportunity.
Thèse d'investissement : forces et faiblesses
- Consensus des analystes : Buy
- Bilan solide avec faible endettement (D/E 3.58)
- Free cash flow positif
- –Actuellement non rentable
- –Positions vendeuses élevées (20.04%)
Aperçu technique
The price is in a transition zone relative to the moving averages — no clear signal.
Profil de risque
The data points to market-like volatility, elevated short interest (20.04%).
Trading Data
Related Stocks in the Same Sector
More Santé stocks
Top peers in the same sector — ranked by market cap.
Where can I buy Azenta, Inc.?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
Live Market Data
Real-time chart, financials, earnings, analysts, insider trades, events & news